Brief: Endo Says Will No Longer Exclude Acquired In-Process R&D Charges From Non-GAAP Performance Measures
29/04/2022 12:17
April 29 (Reuters) - Endo International PLC ENDP.O :
* ENDO - FROM Q1 2022 FINANCIAL REPORTING, WILL NO LONGER
EXCLUDE
ACQUIRED IN-PROCESS RESEARCH & DEVELOPMENT CHARGES FROM NON-GAAP
PERFORMANCE MEASURES
* ENDO INTERNATIONAL - IMPACTS OF CHANGE NOT EXPECTED TO BE
MATERIAL FOR THREE MONTHS ENDED MARCH 31, 2022
Source text for Eikon: ID:
Further company coverage: ENDP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes